Renalys Pharma
Renalys Pharma is a late-stage clinical biopharmaceutical company focused on developing innovative therapeutics to address unmet needs in renal disease management for Japanese and Asian patients. The company obtained the rights to sparsentan, a promising treatment for IgA nephropathy, and is conducting a Phase III clinical trial in Japan. Renalys aims to improve access to new kidney disease treatments in the region.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: ¥6.0Bn
Date: 17-Jul-2024
Investors: Catalys Pacific, SR One, JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank Co., Ltd., Japan Co-Invest IV Limited Partnership, NVCC NO.9 Investment Limited Partnership
Markets: Biopharmaceutical, Healthtech
HQ: Tokyo, Japan
Founded: 2023
Website: https://renalys.com/
Leave a Comment
Comments
No comments yet.